ArticleOncology letters2020

A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.

Junko Takei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.